Methods for inhibiting HIV-1 infection

Details Methods for inhibiting HIV-1 infection Methods for inhibiting HIV-1 infection

2006-06-13

2006-06-13

Parkin, J. S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S154100, C424S139100

Reexamination Certificate

active

07060273

ABSTRACT:
This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

REFERENCES:
patent: 6107019 (2000-08-01), Allaway et al.
patent: 6344545 (2002-02-01), Allaway et al.
patent: 6548636 (2003-04-01), Dragic et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2002/0146415 (2002-10-01), Olson et al.
patent: 2003/0092632 (2003-05-01), Dragic et al.
patent: 2003/0228306 (2003-12-01), Olson et al.
patent: 9641020 (1996-12-01), None
patent: 9726009 (1997-07-01), None
patent: 9737005 (1997-10-01), None
patent: 9747319 (1997-12-01), None
patent: 9856421 (1998-12-01), None
patent: 0035409 (2000-06-01), None
patent: WO0035409 (2000-06-01), None
patent: 0164710 (2001-09-01), None
patent: 0222077 (2002-03-01), None
patent: 02068608 (2002-09-01), None
patent: 02083172 (2002-10-01), None
patent: 03072766 (2003-09-01), None
Grene, et al. Anti-CCR5 antibodies in sera of HIV-positive individuals. Human Immunology, vol. 62, No. 2 (Feb. 2001), pp 143-5 (Exhibit B).
Trkola, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of Virology, vol. 75, No. 2 (Jan. 2001), pp. 579-588 (Exhibit C).
Ditzel, et al. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokine and HIV-1 blocking human anitbodies. Proceedings of the National Academy of Sciences of the United States of America, vol. 95, No. 9 (Apr. 28, 1998), pp. 5241-5245 (Exhibit D).
Vila-Coro, et al. HIV-1 infection through the CCR5 receptor is blocked by receptor di-merization. Proceedings of the National Academy of Sciences of the United States of America, vol. 97, No. 7 (Mar. 28, 2000), pp. 3388-3393 (Exhibit F).
Olson, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Journal of Virology, vol. 73, No. 5 (May 1999), pp. 4145-4155 (Exhibit G).
U.S. Appl. No. 08/663,616, filed Jun. 14, 1996, Allaway et al.
U.S. Appl. No. 60/019,715, filed Jun. 14, 1996, Allaway et al.
U.S. Appl. No. 08/673,682, filed Jun. 25, 1996, Allaway et al.
U.S. Appl. No. 08/665,090, filed Jun. 14, 1996, Allaway et al.
U.S. Appl. No. 60/019,941, filed Jun. 14, 1996, Allaway et al.
U.S. Appl. No. 08/874,570, filed Jun. 13, 1997, Allaway et al.
U.S. Appl. No. 08/874.618, filed Jun. 13, 1997, Allaway et al.
U.S. Appl. No. 09/724,105, filed Nov. 28, 2000, Allaway et al.
U.S. Appl. No. 09/852,238, filed May 9, 2001, Allaway et al.
U.S. Appl. No. 09/212,793, filed Dec. 16, 1998, Olson et al.
U.S. Appl. No. 60/112,532, filed Dec. 16, 1998, Olson et al.
U.S. Appl. No. 09/464,902, filed Dec. 16, 1999, Olson et al.
U.S. Appl. No. 09/594,983, filed Jun. 15, 2000, Olson et al.
U.S. Appl. No. 09/663,219, filed Sep. 15, 2000, Olson et al.
U.S. Appl. No. 60/266,738, filed Feb. 6, 2001, Olson et al.
U.S. Appl. No. 60/282,380, filed Apr. 6, 2001, Olson et al.
U.S. Appl. No. 09/888,938, filed Jun. 25, 2001, Allaway et al.
U.S. Appl. No. 10/323,314, filed Dec. 19, 2002, Dragic et al.
U.S. Appl. No. 08/627,684, filed Apr. 2, 1996, Allaway et al.
U.S. Appl. No. 60/014,532, filed Apr. 2, 1996, Allaway et al.
Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR and Koup RA (1997) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1, Nature Medicine 3: 1389-1393; and.
Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PW, Mosier DE and Burton DR (1999) Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo, Immunity 10: 431-438.
U.S. Appl. No. 10/081,128, filed Feb. 22, 2002, Olson et al.
U.S. Appl. No. 60/358,886, filed Feb. 22, 2002, Olson et al.
U.S. Appl. No. 10/763,545, filed Jan. 23, 2004, Olson et al.
U.S. Appl. No. 09/460,216, filed Dec. 13, 1999, Allaway et al.

Affiliated with

Also associated with

Rating

Methods for inhibiting HIV-1 infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for inhibiting HIV-1 infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting HIV-1 infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3616129